JPEN Journal Club 56. Primary Outcomes

Autor: Ronald L. Koretz
Rok vydání: 2020
Předmět:
Zdroj: Journal of Parenteral and Enteral Nutrition. 45:434-437
ISSN: 1941-2444
0148-6071
DOI: 10.1002/jpen.1947
Popis: AIMS: Low-grade inflammation is believed to contribute to the metabolic dysregulation of obesity. Colchicine can reduce inflammation by inhibiting microtubule propagation and inflammasome assembly. We evaluated efficacy and safety of colchicine for improving metabolic and inflammatory outcomes in people with obesity and metabolic syndrome (MetS). MATERIALS AND METHODS: Adults with obesity and MetS, but who did not have diabetes, were randomized to colchicine 0.6mg or placebo capsules twice daily for three months. The primary outcome was change in insulin sensitivity (S(I)) as estimated by insulin-modified frequently-sampled intravenous glucose tolerance tests. Secondary outcomes included changes in other metabolic parameters and inflammatory markers. RESULTS: Of 40 participants randomized (21 colchicine, 19 placebo), 37 completed the trial. Compared with placebo, colchicine significantly reduced C-reactive protein (p
Databáze: OpenAIRE
Externí odkaz: